Cancers Among US Organ Donors: A Comparison of Transplant and Cancer Registry Diagnoses
Cancers Among US Organ Donors: A Comparison of Transplant and Cancer Registry Diagnoses
复制标题
DOI：
10.1111/ajt.12683
复制
发表时间：
2014-06-01
影响因子：
8.8
通讯作者：
Kasiske, B.
中科院分区：
文献类型：
--
作者：
Engels, E. A.;Castenson, D.;Kasiske, B.
癌症传播是危及生命的移植并发症。监测移植实践需要完整记录供体癌症。美国移植受者科学登记处 (SRTR) 记录了已故捐献者（从 1994 年开始）和活体捐献者（2004 年）的癌症情况。我们将 SRTR（52 599 名捐赠者，110 762 名移植者）与州癌症登记处联系起来。癌症登记处发现 519 名捐献者患有癌症：373 名已故捐献者 (0.9%) 和 146 名活体捐献者 (1.2%)。在已故捐献者中，50.7%的癌症是脑肿瘤。活体捐献者中，54.0%是捐献后确诊的；大多数是普通人群中常见的癌症（例如乳腺癌、前列腺癌）。 SRTR 或癌症登记处有 1063 名已故捐献者被诊断患有癌症，其中 107 名捐献者 (10.1%) 没有被 SRTR 诊断出癌症。有 103 名活体捐献者在捐献前或捐献时患有癌症，并在 SRTR 或癌症登记处得到诊断，其中 43 名 (41.7%) 没有被 SRTR 诊断为癌症。 SRTR 不记录活体捐赠者捐献后的癌症，因此遗漏了癌症登记处记录的 81 种癌症。总之，供体癌症并不常见，但某些病例缺乏记录，凸显了器官采购组织和移植计划需要改进确定和报告。
Transmission of cancer is a life-threatening complication of transplantation. Monitoring transplantation practice requires complete recording of donor cancers. The US Scientific Registry of Transplant Recipients (SRTR) captures cancers in deceased donors (beginning in 1994) and living donors (2004). We linked the SRTR (52 599 donors, 110 762 transplants) with state cancer registries. Cancer registries identified cancers in 519 donors: 373 deceased donors (0.9%) and 146 living donors (1.2%). Among deceased donors, 50.7% of cancers were brain tumors. Among living donors, 54.0% were diagnosed after donation; most were cancers common in the general population (e. g. breast, prostate). There were 1063 deceased donors with cancer diagnosed in the SRTR or cancer registry, and the SRTR lacked a cancer diagnosis for 107 (10.1%) of these. There were 103 living donors with cancer before or at donation, diagnosed in the SRTR or cancer registry, and the SRTR did not have a cancer diagnosis for 43 (41.7%) of these. The SRTR does not record cancers after donation in living donors and so missed 81 cancers documented in cancer registries. In conclusion, donor cancers are uncommon, but lack of documentation of some cases highlights a need for improved ascertainment and reporting by organ procurement organizations and transplant programs.